On November 4, 2021, Behenna, Douglas; Deckhut, Charlotte; Rovira, Alexander; Goldberg, Steven; Kummer, David; Keith, John; Woods, Craig; Rhorer, Timothy; Tanis, Virginia; Martin, Connor; Meduna, Steven; McCarver, Stefan; Valdes, Alexander; Loskot, Steven; Xue, Xiaohua published a patent.Safety of 5-Isopropylnicotinic acid The title of the patent was Imidazopyridazines as modulators of IL-17 in the treatment of inflammatory disorders. And the patent contained the following:
The invention relates compounds of formula I, preparation and use in treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease. Compound I, wherein R1 is (un)substituted C1-6 alkyl, (un)substituted C0-2 alkyl-C3-6 cycloalkyl, and (un)substituted 5- and 6-membered heterocyclyl having 1 and 2 nitrogen atoms; R2 is H, C3-5 cycloalkyl and (un)substituted C1-4 alkyl; R3 is (un)substituted C0-1 alkyl-C3-6 cycloalkyl, (un)substituted C3-6 alkyl and (un)substituted C1-2 alkyl-O-C1-3 alkyl; R4 is (un)substituted C3-6 cycloalkyl, (un)substituted Ph and (un)substituted 5- and 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O and S; R5 is H and halo; and pharmaceutically acceptable salts thereof, are claimed. Compound II was prepared using a multistep procedure (procedure given). Compound II was evaluated for IL-17A modulatory activity resulting in an IC50 of 0.18μM and 0.30μM using Eu-HTRF and NHK assays, resp. Compounds of the invention were evaluated for IL-17A modulatory activity (data given). The experimental process involved the reaction of 5-Isopropylnicotinic acid(cas: 73591-69-2).Safety of 5-Isopropylnicotinic acid
The Article related to imidazopyridazine preparation modulator il 17 inflammatory disorder, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Safety of 5-Isopropylnicotinic acid